CBD Supplementation in Brazilian Jiu-Jitsu Athletes

Sponsor
Associação Pan-Americana Multidisciplinar de Endocanabinologia
Study ID
NCT07552974
Phase
PHASE2/PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Pain
  • Pro and Anti Inflamatory Cytokines
  • Quality of Life
  • Sleep

Eligibility Criteria

Sex
MALE
Age
18 Years - 40 Years
Healthy Volunteers
Accepted

Interventions

  • CBD Isolate 100mg BID — DRUG
    Treated for 12 weeks
  • Placebo — OTHER
    Equivalent volume of MCT BID

Study Details

Brazilian Jiu-Jitsu (BJJ) is a high-intensity martial art that imposes significant physical and physiological demands on practitioners, including rigorous training and frequent competitions, which can result in chronic inflammation, delayed-onset muscle soreness (DOMS), sleep disturbances, and reduced quality of life. Effective recovery strategies are essential to optimize athletic performance and longevity in the sport. Cannabidiol (CBD), a non-psychotomimetic phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties. Preclinical studies indicate that CBD modulates inflammatory pathways, such as inhibition of NF-κB and NLRP3, thereby reducing pro-inflammatory cytokines such as IL-6, TNF-α, IL-8, and IL-1β, while increasing the anti-inflammatory cytokine IL-10. In clinical contexts, CBD has shown potential to attenuate DOMS and improve sleep without the adverse effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). However, evidence in BJJ athletes remains limited, with gaps in the translation of preclinical findings to healthy athletic populations. The prevalence of injuries in combat sports can reach 28%, with contusions and sprains being common and further exacerbating inflammation and pain. Although approximately 23.4% of athletes report cannabis use, there is a lack of randomized controlled trials (RCTs) specifically for BJJ evaluating isolated CBD at standardized doses. Furthermore, concerns regarding hepatotoxicity, monitored through enzymes such as AST and ALT, require rigorous safety evaluation. This protocol describes an RCT to investigate the effects of 200 mg/day of isolated CBD for 12 weeks in BJJ athletes, focusing on sensitive inflammatory markers (IL-6 as the primary pro-inflammatory marker and IL-10 as the anti-inflammatory marker), pain, sleep, and quality of life. The study aims to address gaps identified in systematic reviews and provide an evidence-based foundation for future recommendations.

Key Dates

First listed
Apr 27, 2026
Start date
Jun 1, 2026
Status verified
Apr 2026
Primary completion
Feb 1, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm CBD, recieving 100mg BID
    CBD 200mg daily
  • Placebo Comparator: Placebo, recieving MCT OIL (equivalent volume of 100mg of CBD) BID
    Placebo BID

Primary Outcome Measure

Inflammatory cytokines [ Time Frame: From enrollment to the end of treatment at 12 weeks ]

Central Contacts

Related Studies